Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
COMPASS Pathways Plc - American Depository Shares
(NQ:
CMPS
)
4.420
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 22, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about COMPASS Pathways Plc - American Depository Shares
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD
March 01, 2024
The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.
Via
Talk Markets
Compass Pathways Plc (CMPS) Q4 2023 Earnings Call Transcript
February 29, 2024
CMPS earnings call for the period ending December 31, 2023.
Via
The Motley Fool
Topics
Earnings
Compass Pathways Shows Robust 2023 Year-End Results, Embraces Clinical Milestones For Psilocybin As Depression Treatment
February 29, 2024
Via
Benzinga
Podcast - Post-Frenzy Psychedelics Investing And Reclaiming The Right To Pursue Happiness With Zappy Zapolin: '2024 Is When It Goes Mainstream'
February 29, 2024
Via
Benzinga
Earnings Scheduled For February 29, 2024
February 29, 2024
Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.
Via
Benzinga
Earnings Preview For Compass Pathways
February 28, 2024
Via
Benzinga
Psilocybin Mushrooms For Sale: Is It Legal Anywhere In America?
February 02, 2024
Via
Benzinga
Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
February 29, 2024
Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.
Via
Benzinga
Penny Power Players: 3 Stocks to Watch in the Microcap Arena
February 27, 2024
Dive into three microcap stocks set to skyrocket with innovative strategies and sector leadership. Don't miss out.
Via
InvestorPlace
Mental Health Mavericks: 3 Stocks Changing the Game
February 21, 2024
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money.
Via
InvestorPlace
Wall Street Says Compass Pathways Could Rise 307%. Here's How It Could Actually Happen.
February 19, 2024
The lofty target is closer to being within reach than it may seem at first.
Via
The Motley Fool
Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex
February 18, 2024
IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...
Via
Talk Markets
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
Why Is MindMed (MNMD) Stock Up 8% Today?
February 12, 2024
MindMed and other psychedelic stocks are rising today on news of an FDA priority review. Here's what this means for MNMD stock and its peers.
Via
InvestorPlace
5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week
January 30, 2024
The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.
Via
Talk Markets
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More
January 26, 2024
Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.
Via
Benzinga
New Study Reveals Suggestibility's Role In Antidepressant Effects Of Psilocybin Therapy
January 25, 2024
Study found that suggestibility did not predict response to psilocybin therapy for MDD patients, challenging concerns about placebo effects.
Via
Benzinga
How Psychedelic-Based Therapeutics Are Advancing in Treating Generalized Anxiety Disorder (GAD) Condition
January 24, 2024
EQNX::TICKER_START (NYSE:CYBN),(NASDAQ:CMPS),(NASDAQ:MNMD),(NASDAQ:SEEL),(NASDAQ:ATAI) EQNX::TICKER_END
Via
FinancialNewsMedia
Psychedelics Headlines: MDMA & Coping Skills In PTSD, LSD's Perceived Risks, Knowledge Gaps, Surveys & More
January 15, 2024
Welcome to Benzinga's weekly psychedelics headlines roundup. This is our pick of must-read news items from the second week of January 2024.
Via
Benzinga
5 Largest Psychedelic Drug Stocks Advanced Slightly Last Week
January 13, 2024
The munKNEE Psychedelic Drug Stocks Index went up 2.3% last week and is now up 1.8% MTD.
Via
Talk Markets
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
Therapy’s New Frontier: 3 Psychedelic Stocks for the Mental Health Revolution
January 09, 2024
Psychedelic stocks have been making big moves beneath the surface, and the sector's popularity might spark again in 2024.
Via
InvestorPlace
3 Big New Catalysts for Psychedelics Stocks in 2024
January 08, 2024
This could be the year that psychedelics stocks start to fly.
Via
The Motley Fool
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
January 06, 2024
A decade after it was founded as a wholly-owned subsidiary of the Multidisciplinary Association for Psychedelic Studies (MAPS), MAPS Pub
Via
Benzinga
Mental Health Treatment: Compass Pathways And Greenbrook TMS Join Forces For Psilocybin Therapy Research
January 05, 2024
Biotechnology company Compass Pathways plc (NASDAQ: CMPS) and Greenbrook TMS Inc (NASDAQ: GBNH) have entered into a three-year research collaboration agreement to explore delivery models
Via
Benzinga
AMA's Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here's What To Expect
January 03, 2024
The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for...
Via
Benzinga
Psychedelic Stock Gainers And Losers From January 1, 2024
January 01, 2024
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
...
30
31
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.